Gleevec Tablet
Product Images NDC 0078-0401

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gleevec (NDC 0078-0401). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Imatinib Structural Formula (Gleevec 01)

Imatinib Structural Formula (Gleevec 01)
FDA Label Image

Figure 1 Progression Free Survival (itt Principle) (Gleevec 02)

Figure 1 Progression Free Survival (itt Principle) (Gleevec 02)
FDA Label Image

Figure 2 Time To Progression To Ap Or Bc (itt Principle) (Gleevec 03)

Figure 2 Time To Progression To Ap Or Bc (itt Principle) (Gleevec 03)
FDA Label Image

Figure 3: Study 1 Recurrence-free Survival (itt Population) (Gleevec 04)

Figure 3: Study 1 Recurrence-free Survival (itt Population) (Gleevec 04)
FDA Label Image

Figure 4: Study 2 Recurrence-free Survival (itt Population) (Gleevec 05)

Figure 4: Study 2 Recurrence-free Survival (itt Population) (Gleevec 05)
FDA Label Image

Figure 5: Study 2 Overall Survival (itt Population) (Gleevec 06)

Figure 5: Study 2 Overall Survival (itt Population) (Gleevec 06)
FDA Label Image

Principal Display Panel – Package Label – 100 mg Tablets (Gleevec 07)

Principal Display Panel – Package Label – 100 mg Tablets (Gleevec 07)
This appears to be a mix of random letters, numbers, and symbols, with some mentioning of tablets containing imatirib mesylate. As a result, a useful description cannot be generated. It is likely that the text was not accurately recognized by the tool or sections of a document were scanned instead of an intended page.*
FDA Label Image

Principal Display Panel – Package Label – 400 mg Tablets (Gleevec 08)

Principal Display Panel – Package Label – 400 mg Tablets (Gleevec 08)
This is the description for the medicine Gleevec. Gleevec is a medicine containing Imatinib Mesylate used in the treatment of cancer. Each tablet contains 400 mg of the active ingredient. The product is prescription-only. It should be stored in USP-controlled room temperature and protected from moisture. The text also contains manufacturing information, dosage instructions, and safety information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.